Medikit (7749) · FactRestated
Impact on Interventional Products from the Termination of the Sales Agreement with Boston Scientific
First written in FY2025-H1. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Business Impact from Termination or Unfavorable Amendment of Important ContractsA theme 110 companies write about · 117 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 6 of 30 companies on the "Worse" side.
56 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 110 companies compared. The sentences above are computed from all 110.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Overseas, revenue from interventional products declined because the sales agreement with Boston Scientific Corporation ended in March 2024.」
The full-year results reconfirm the impact of lower overseas revenue from interventional products following the termination of the sales agreement in March 2024. - FY2025-H1First statedAnnual report
「Overseas, revenue from interventional products declined because the sales agreement with Boston Scientific Corporation ended in March 2024.」
The disclosure states that the sales agreement with Boston Scientific Corporation ended in March 2024, resulting in lower overseas revenue from interventional products.